Nicotine Regulatory Consultancy

Guiding Tobacco Manufacturers Through the Regulatory Challenges to Market

The FDA and other regulators are paying close attention to the nicotine industry, which means manufacturers need to understand the impact of their product and be able to demonstrate harm mitigation.

Where McKinney RSA Comes In

Our collective of toxicologists, chemists, behavioral scientists, and research professionals, with a cumulative experience exceeding two centuries deeply engaged in nicotine regulation, is primed to swiftly comprehend the nuances of your business hurdles and design bespoke studies that align with your financial constraints.


Using history as our guide, McKinney RSA’s consortium of experts balances your needs with the regulatory environment. We quickly establish trust with your team so that we can:

  • Find the right mix between product innovation and harm reduction
  • Create custom studies that live at the intersection of best practice and your business maturity
  • Efficiently navigate regulatory submission processes
  • Maintain compliance and help you leverage your data to influence the industry
  • Help build your expertise within the nicotine industry

Our Nicotine Services Include:

Getting a nicotine product to market, and staying in regulatory compliance, is no small feat. Got questions on the process? We’ve got answers.

Our Insights

  • Cannabis Science Conference Logo

    2 min. read

    2024 Cannabis Science Conference Recap

    We recently had the pleasure of participating in the Cannabis Science Conference 2024, a premier event that brought together industry leaders, scientists, and regulatory experts to share their insights and advancements in the field. Our social media coverage highlighted several key moments from the conference, showcasing the breadth of knowledge and innovation present. Read More

  • CannMed Group Image

    2 min. read

    CannMed24 Conference Recap: Pioneering the Future of Cannabis in Biopharma

    The CannMed24 conference, held from May 12-15, was a valuable event for professionals in the cannabis and biopharma industries. This year’s gathering highlighted the burgeoning partnership between biopharma companies and the cannabis sector, driven by both anecdotal evidence of cannabis’ benefits and an increasing demand for scientifically rigorous research and development. Read More

  • 3 min. read

    Quitting Camel Country

    Here’s what Cheryl Olson says she learned while writing her latest Tobacco Reporter article, about smoking and harm reduction in Middle East nations.  Read More

Contact Us

"*" indicates required fields

Name*
Newsletter
By clicking submit, I am providing my electronic signature expressly authorizing McKinney Regulatory Science Advisors, LLC to contact me by email, phone, or text (including by a live representative, an automatic dialing system, or artificial/pre-recorded voice) at the phone number and email I provided above and any phone and/or email numbers I may provide in the future. I understand I am not required to sign/agree to this as a condition to purchase.
Back to top